// about

Advancing precision medicine

Theranostics is among the most promising and rapidly advancing areas of oncology.
Ascinta develops the software and provides the expertise that make radiopharmaceutical therapy more personalized, more scalable, and more widely accessible.

Our story and purpose

Voxel-art orca over the Vancouver skyline

  1. Ascinta is built on decades of research and operational experience at the frontier of quantitative nuclear imaging. Our research legacy is rooted in Vancouver’s nuclear medicine and imaging ecosystem, which for more than half a century helped develop and validate many of the methods the field relies on today, across image reconstruction, quantification, radiopharmaceutical dosimetry, and AI-based processing.

  2. Working at that frontier, we encountered the same gap repeatedly: quantification methods and models developed in research were not reaching clinical practice, and the quantitative information contained in PET and SPECT images remained “locked”, rarely used to improve patient care.

  3. Closing that gap is our purpose. By combining rigorous science, modern software engineering, and expert services, we turn images into actionable data and insights, from acquisition and calibration through quantification to the final report - so that drug development and patient treatment decisions are more informed.

// team

Leadership team

A legacy in quantitative nuclear imaging and therapy, AI-driven image computing, and theranostics — combining scientific knowledge with clinical insight.

// collective expertise
  • Image reconstruction
  • Quantitative SPECT & PET
  • Radiopharmaceutical dosimetry
  • Protocols and workflows
  • Quantification
  • Kinetic modeling
  • Radiomics and AI
Ivan Klyuzhin, PhD

Ivan Klyuzhin, PhD

Chief Executive Officer &
Co-Founder

Arman Rahmim, PhD, DABSNM

Arman Rahmim, PhD, DABSNM

Chief Scientific Officer &
Co-Founder

Carlos Uribe, PhD, MCCPM

Carlos Uribe, PhD, MCCPM

Chair of the Board &
Co-Founder

Pedro Esquinas, PhD, MCCPM

Pedro Esquinas, PhD, MCCPM

Chief Product Officer

Our values

  • Care

    We put people first — caring for one another, helping each other succeed, and prioritizing the well-being of patients, clients, and peers.

  • Innovation

    We challenge conventions and embrace creative thinking to develop transformative solutions.

  • Openness

    We welcome new ideas and diverse perspectives, form strong partnerships, and respect personal choice and autonomy.

  • Integrity

    We hold to the highest ethical standards in every decision and action, and we stand with the research community.

  • Passion

    We are driven by a deep commitment to science, progress, and the pursuit of meaningful impact.

// our mission To elevate cancer care through technologies that enable personalized and accessible radiopharmaceutical therapies.

Ascinta

// our foundational belief Rigorous science, forward thinking, and collaboration are cornerstones of meaningful contributions to healthcare.

  • Rigorous science

    Every method is grounded in evidence, validated against reference standards, and held to the highest scientific quality.

  • Forward thinking & disciplined work

    We pair first-principles thinking with the execution discipline to turn ambitious ideas into deployable, real-world tools.

  • Open collaboration & dissemination

    We actively partner with academia, healthcare institutions, and industry to advance new ideas and transform standard of care.

How we work

A shared set of operating principles that shape how we build, decide, and collaborate every day.

  • Methodical and thorough

    We build thought-out solutions and favor clarity over ambiguity. We think things through, and never shy away from hard work that matters.

  • Iterative continuous improvement

    We stay nimble. Rather than wait for a perfect answer or solution, we compartmentalize, ship, and improve one step at a time.

  • Planning ahead

    We aren't afraid of change or innovation. We anticipate challenges and opportunities before they arrive, rather than reacting once they do.

  • Seeking feedback

    We listen, ask for second opinions, and learn from one another and from our partners — constantly.

Partners across the theranostic pathway

We work as an extension of our partners' teams — bringing specialized expertise, tools, and algorithms to the people advancing radiopharmaceutical therapy.

  • Drug developers

    Radiopharmaceutical developers who need trustworthy, quantitative imaging endpoints to guide dosing decisions and demonstrate efficacy.

  • CROs

    Contract research organizations running imaging-intensive trials that demand standardized, reproducible analysis across sites and timepoints.

  • Theranostics clinics

    Clinical teams delivering radiopharmaceutical therapy who need dependable dosimetry and response assessment for every patient.

  • Academic & research groups

    Investigators advancing the science, who need advanced tools and methodological support to turn ideas into evidence.

Let's build the future of theranostics together

Whether you're a software, clinical, or research partner, we'd love to explore how we can work together — reach out and start the conversation.

Get in touch